AD target discovery

Some neuropathologic features of AD have been well characterized, but it is still unclear what mechanism is responsible for the occurrence and development of the disease. Aβ plaques, neurofibrillary tangles, as well as cholinergic neuron damages, oxidative stress and inflammatory reactions in AD patients, all of these pathological expressions are obviously linked to each other. However, determining the origins of “chicken” and “egg” on a global scale is rather sophisticated, making the development of effective and radical therapies particularly difficult. Despite this, we still hope to help people better understand the disease and advance basic research to the early diagnosis and treatment of the disease by leveraging our comprehensive and powerful technology platform. The accumulation of long-term experience in the fields of biology, chemistry and crossover fields of life sciences (such as computer science) gives us the strength to study the pathogenesis of the disease in depth.

Pre-clinical Development
As a leader in the field of life science, Alzheimacy has established an integrated antibody discovery and engineering platform. Our comprehensive antibody development capabilities include but are not limited to target discovery and validation, surface display technologies and antibody library screening, antibody humanization and affinity maturation, pilot production of therapeutic antibodies, efficacy study and safety evaluation of therapeutic antibodies.

		From	To	From	To	From	To
Monday	Open
Tuesday	Open
Wednesday	Open
Thursday	Open
Friday	Open
Saturday	Open
Sunday	Open